HealthVerity to acquire Symphony Health, combining clinical and commercial data
What's the deal? HealthVerity, a real-world data exchange and patient identity platform, is acquiring Symphony Health, a commercial healthcare data and analytics company. The deal is expected to close in May 2026. Together, the companies aim to build what HealthVerity calls "the nation's leading patient-centric real-world and commercial data ecosystem."
Symphony Health offers data aggregation, consulting services, market intelligence tools, and support for health economics and outcomes research. HealthVerity helps life sciences companies, payers, and government entities find patients for research, answer questions using real-world data, and link patient records across datasets.
Why now? Symphony Health has changed hands multiple times since its 2012 founding. PRA Health Sciences acquired it in 2017 for $530M in cash, and ICON plc subsequently bought PRA in 2021. Symphony has been operating as a subsidiary of ICON, a publicly traded clinical research organisation.
HealthVerity, meanwhile, has built up significant capital. It raised $7.1M in Series A (2016), $10M in Series B (2017), $25M in Series C (2019), and $100M in Series D (2021) — giving it the firepower for a major acquisition.
"This will allow us to rapidly innovate in developing the next generation of real-world data and applications, giving organisations across the healthcare ecosystem more dynamic and actionable insights to make better and faster decisions," said Andrew Kress, HealthVerity's chief executive officer.
What could go wrong? Merging two complex data platforms is never simple. Integrating Symphony Health's legacy systems — built up through its own series of acquisitions — with HealthVerity's infrastructure could prove challenging. There's also the question of whether customers of both companies will see continuity of service during the transition.
The signal: The deal reflects a broader trend in healthcare data: consolidation. As life sciences companies demand richer, more connected datasets to support drug development, commercialisation, and outcomes research, platforms that can stitch together clinical and commercial data in one place hold a growing advantage. Expect more M&A in this space as the race to build comprehensive healthcare data ecosystems intensifies.
Read more: mobihealthnews.com
